GHRS
NASDAQ HealthcareGH Research PLC - Ordinary Shares
Biotechnology
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
๐ Market Data
| Price | $21.50 |
|---|---|
| Volume | 345,100 |
| Market Cap | 1.48B |
| Beta | 1.320 |
| RSI (14-Day) | 52.2 |
| 200-Day MA | $21.53 |
| 50-Day MA | $24.21 |
| 52-Week High | $31.44 |
| 52-Week Low | $12.04 |
| Forward P/E | -11.62 |
| Price / Book | 4.11 |
๐ฏ Investment Strategy Scores
GHRS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (75/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (17/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find GHRS in your text
Paste any article, transcript, or post โ the tool will extract GHRS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-10-29.